Use of pasteurized

1. A method for treating a metabolic disorder in a human subject in need thereof comprising orally administering a therapeutically effective amount of pasteurized Akkermansia muciniphila or fragments thereof to the subject, wherein the Akkermansia muciniphila has been pasteurized at a temperature in a range of from 50° C. to 100° C. prior to administration, thereby treating the metabolic disorder in the subject.

2. The method according to claim 1 , wherein said metabolic disorder is obesity.

3. The method according to claim 1 , wherein said metabolic disorder is selected from the group consisting of metabolic syndrome; insulin-deficiency or insulin-resistance related disorders; Diabetes Mellitus including Type 2 Diabetes; glucose intolerance; abnormal lipid metabolism; atherosclerosis; hypertension; pre-eclampsia; cardiac pathology; stroke; non-alcoholic fatty liver disease; hyperglycemia; hepatic steatosis; liver diseases including fibrosis associated with obesity and abnormal liver functions, selected from changes in bile production and immunity; dyslipidemia; dysfunction of the immune system associated with overweight and obesity; inflammatory, immune and barrier function diseases selected from inflammatory bowel disease, Crohn's disease, ulcerative colitis, and irritable bowel syndrome; cardiovascular diseases; high cholesterol; elevated triglycerides; asthma; sleep apnea; osteoarthritis; neuro-degeneration; gallbladder disease; syndrome X; atherogenic dyslipidemia and cancer.

4. The method according to claim 1 , wherein the therapeutically effective amount is an amount of Akkermansia muciniphila ranging from about 1.10 4 to about 1.10 12 cells.

5. The method according to claim 1 , wherein the therapeutically effective amount of Akkermansia muciniphila is administered at least three times a week.

6. The method according to claim 1 , wherein the therapeutically effective amount of Akkermansia muciniphila is co-administered with another probiotic strain and/or another bacteria and/or microorganisms with beneficial effects and/or with one or more prebiotics.

7. The method according to claim 1 , wherein the therapeutically effective amount of Akkermansia muciniphila or fragment thereof is contained in a composition in association with an excipient.

8. The method according to claim 1 , wherein the therapeutically effective amount of Akkermansia muciniphila or fragment thereof is contained in a nutritional composition.

9. The method according to claim 1 , wherein the therapeutically effective amount of Akkermansia muciniphila or fragment thereof is contained in a pharmaceutical composition in association with a pharmaceutically acceptable vehicle.

10. A method for promoting weight loss in a human subject in need thereof comprising orally administering a therapeutically effective amount of pasteurized Akkermansia muciniphila or fragments thereof to the subject, wherein the Akkermansia muciniphila has been pasteurized at a temperature in a range of from 50° C. to 100° C. prior to administration, thereby promoting weight loss in the subject.

11. The method according to claim 10 , wherein the method increases energy expenditure of the subject.

12. The method according to claim 10 , wherein said method does not impact the food intake of said subject.

13. The method according to claim 10 , wherein the therapeutically effective amount is an amount of Akkermansia muciniphila ranging from about 1.10 4 to about 1.10 12 cells.

14. The method according to claim 10 , wherein the method increases satiety in the subject.